Matthew Sykes
Stock Analyst at Goldman Sachs
(3.57)
# 835
Out of 4,915 analysts
205
Total ratings
47.89%
Success rate
5.91%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $5.93 | -15.68% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $3.53 | -14.89% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $14.01 | -53.60% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $40.62 | +10.78% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $4.05 | +97.53% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $34.55 | +38.93% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $11.78 | +44.31% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $177.75 | -9.99% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $5.07 | +97.24% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $90.20 | +38.58% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $13.71 | +2.12% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $203.08 | +18.18% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $12.48 | +108.33% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $174.50 | -2.58% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $41.32 | +35.53% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $100.24 | -20.19% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.48 | +1.69% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $137.41 | +38.27% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.78 | +125.75% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.40 | +77.45% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $23.90 | +54.81% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $49.42 | +31.53% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $190.49 | +31.24% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.89 | +307.47% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,259.87 | +3.19% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $13.39 | -10.38% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $482.59 | +32.62% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $117.66 | +23.24% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $50.29 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $5.93
Upside: -15.68%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $3.53
Upside: -14.89%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $14.01
Upside: -53.60%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $40.62
Upside: +10.78%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $4.05
Upside: +97.53%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $34.55
Upside: +38.93%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $11.78
Upside: +44.31%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $177.75
Upside: -9.99%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $5.07
Upside: +97.24%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $90.20
Upside: +38.58%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $13.71
Upside: +2.12%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $203.08
Upside: +18.18%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $12.48
Upside: +108.33%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $174.50
Upside: -2.58%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $41.32
Upside: +35.53%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $100.24
Upside: -20.19%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.48
Upside: +1.69%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $137.41
Upside: +38.27%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.78
Upside: +125.75%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.40
Upside: +77.45%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $23.90
Upside: +54.81%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $49.42
Upside: +31.53%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $190.49
Upside: +31.24%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.89
Upside: +307.47%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,259.87
Upside: +3.19%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $13.39
Upside: -10.38%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $482.59
Upside: +32.62%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $117.66
Upside: +23.24%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $50.29
Upside: -